TG Therapeutics/$TGTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Ticker

$TGTX
Primary listing

Industry

Biotechnology

Employees

352

ISIN

US88322Q1085

TG Therapeutics Metrics

BasicAdvanced
$5.7B
164.57
$0.24
2.21
-

What the Analysts think about TG Therapeutics

Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.

Bulls say / Bears say

TD Cowen initiated coverage of TG Therapeutics with a 'Buy' recommendation and a price target of $50, indicating confidence in the company's growth prospects. (nasdaq.com)
Analysts have set an average price target of $40.67 for TG Therapeutics, suggesting potential upside from current levels. (americanbankingnews.com)
The company's revenue increased by 40.80% in 2024 compared to the previous year, reflecting strong financial performance. (stockanalysis.com)
StockNews.com downgraded TG Therapeutics to a 'Sell' rating, indicating potential concerns about the company's outlook. (defenseworld.net)
Insider selling activity, such as Director Sagar Lonial selling 5,000 shares, may signal a lack of confidence among company insiders. (etfdailynews.com)
The company's debt-to-equity ratio of 1.27 indicates a relatively high level of debt, which could pose financial risks. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TG Therapeutics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TG Therapeutics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TGTX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs